Impact of Medicaid expansion on racial disparities among patients with gastrointestinal cancer.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
052 patients were included in this analysis, including 19,188 patients with PDAC, 60,404 with CRC, and 6460 with GC.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Medicaid expansion was associated with a greater reduction in 2-year mortality rates among Black patients residing in MES compared to those residing in non-MES. Existing racial disparities in mortality remained the same or worsened in non-MES but were mitigated in MES following Medicaid expansion in almost all comparisons.
[BACKGROUND] Racial minority groups experience disparities in cancer treatment and mortality.
- p-value p < .001
- p-value p = .047
- 95% CI -5.7 to -0.04
- 연구 설계 cross-sectional
APA
Manisundaram N, Snyder RA, et al. (2025). Impact of Medicaid expansion on racial disparities among patients with gastrointestinal cancer.. Cancer, 131(9), e35879. https://doi.org/10.1002/cncr.35879
MLA
Manisundaram N, et al.. "Impact of Medicaid expansion on racial disparities among patients with gastrointestinal cancer.." Cancer, vol. 131, no. 9, 2025, pp. e35879.
PMID
40267029 ↗
Abstract 한글 요약
[BACKGROUND] Racial minority groups experience disparities in cancer treatment and mortality. This study aimed to investigate the effect of Medicaid expansion on the existing racial disparities in all-cause mortality among patients with gastrointestinal malignancies.
[METHODS] A cross-sectional cohort study of patients with pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and gastric adenocarcinoma (GC) of any stage was conducted using data from the National Cancer Database (2009-2019). Using difference-in-difference (DID) analysis, the authors compared adjusted 2-year mortality rates among Black and White patients residing in states with expanded Medicaid benefits (MES) and non-MES before (2009-2013) and after (2014-2019) Medicaid expansion.
[RESULTS] A total of 86,052 patients were included in this analysis, including 19,188 patients with PDAC, 60,404 with CRC, and 6460 with GC. Two-year mortality rates decreased among Black patients with PDAC residing in MES but not those residing in non-MES following Medicaid expansion (DID, -9.4%; 95% confidence interval [CI], -14.4% to -4.4%; p < .001). Mortality decreased more among Black and White patients with CRC in MES compared to those in non-MES following Medicaid expansion (DID, -2.9%; 95% CI, -5.7 to -0.04; p = .047 and DID, -4.2%; 95% CI, -5.8 to -2.5; p < .001, respectively). Black patients with GC in MES experienced a marked reduction in mortality compared to those in non-MES (DID, -7.7%, 95% CI, -16.1 to 0.56; p = .07).
[CONCLUSION] Medicaid expansion was associated with a greater reduction in 2-year mortality rates among Black patients residing in MES compared to those residing in non-MES. Existing racial disparities in mortality remained the same or worsened in non-MES but were mitigated in MES following Medicaid expansion in almost all comparisons.
[METHODS] A cross-sectional cohort study of patients with pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and gastric adenocarcinoma (GC) of any stage was conducted using data from the National Cancer Database (2009-2019). Using difference-in-difference (DID) analysis, the authors compared adjusted 2-year mortality rates among Black and White patients residing in states with expanded Medicaid benefits (MES) and non-MES before (2009-2013) and after (2014-2019) Medicaid expansion.
[RESULTS] A total of 86,052 patients were included in this analysis, including 19,188 patients with PDAC, 60,404 with CRC, and 6460 with GC. Two-year mortality rates decreased among Black patients with PDAC residing in MES but not those residing in non-MES following Medicaid expansion (DID, -9.4%; 95% confidence interval [CI], -14.4% to -4.4%; p < .001). Mortality decreased more among Black and White patients with CRC in MES compared to those in non-MES following Medicaid expansion (DID, -2.9%; 95% CI, -5.7 to -0.04; p = .047 and DID, -4.2%; 95% CI, -5.8 to -2.5; p < .001, respectively). Black patients with GC in MES experienced a marked reduction in mortality compared to those in non-MES (DID, -7.7%, 95% CI, -16.1 to 0.56; p = .07).
[CONCLUSION] Medicaid expansion was associated with a greater reduction in 2-year mortality rates among Black patients residing in MES compared to those residing in non-MES. Existing racial disparities in mortality remained the same or worsened in non-MES but were mitigated in MES following Medicaid expansion in almost all comparisons.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.